Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ZERVIATE 0.24% EYE DROP

cetirizine
$7.3243per EA

Strength

2.4 mg/mL

Manufacturer

Harrow Eye, LLC

NDC

82667001524

Classification

Brand

Dosage Form

FOR SOLUTION

Route

OPHTHALMIC

Last Updated

4/22/2026

Active Ingredients

CETIRIZINE

Approval Type

New Drug (NDA)

FDA Application

NDA208694

On Market Since

4/30/2025

Pharmacological Classes

Histamine H1 Receptor Antagonists
Histamine-1 Receptor Antagonist

Price History

1W

0.0%

1M

-0.2%

3M

-0.4%

6M

-0.4%

1Y

N/A

3Y

N/A

5Y

N/A

All

-0.4%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

ZZZQUIL 50 MG/30 ML LIQUID
Brand
37000050012•The Procter & Gamble Manufacturing Company
$0.0204
per ML
THERAFLU EXPRESSMAX COLD NT LQ
Brand
00067812908•Haleon US Holdings LLC
$0.0221
per ML
ZZZQUIL 50 MG/30 ML LIQUID
Brand
37000050006•The Procter & Gamble Manufacturing Company
$0.0236
per ML
ROBITUSSIN LONG-ACTING LIQ
Brand
00031869312•Haleon US Holdings LLC
$0.0375
per ML
ADVIL PM CAPLET
Brand
00573016405•Haleon US Holdings LLC
$0.1651
per EA
ADVIL PM CAPLET
Brand
00573016420•Haleon US Holdings LLC
$0.1651
per EA
ADVIL PM CAPLET
Brand
00573016430•Haleon US Holdings LLC
$0.1651
per EA
ADVIL PM CAPLET
Brand
00573016440•Haleon US Holdings LLC
$0.1651
per EA
ADVIL PM CAPLET
Brand
00573016443•Haleon US Holdings LLC
$0.1651
per EA
ADVIL PM LIQUI-GELS
Brand
00573016725•Haleon US Holdings LLC
$0.1985
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy